First patients receive experimental drug for aggressive ovarian cancer
NCT ID NCT07226427
Summary
This is the first time researchers are testing a new drug called MEN2501 in people with ovarian cancer that has stopped responding to standard platinum-based chemotherapy. The study aims to find a safe dose, understand how the drug works in the body, and see if it can help control the cancer. It will involve about 100 adults with specific types of advanced ovarian, fallopian tube, or primary peritoneal cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NEXT Virginia
RECRUITINGFairfax, Virginia, 22031, United States
Conditions
Explore the condition pages connected to this study.